Boston Scientific has recently reported the results of the Optical Coherence Tomography Drug Eluting Stent Investigation (OCTDESI)trial; part of the JACTAX stent program. [30] The JACTAX stent con ...

which includes our drug-eluting stents and our drug-coated balloon, is now growing close to double digits with drug-eluting stents at now less than 5%. That's less than 5% of our total company ...

This particularly applies to tech giants and popular consumer-facing stocks.What if you'd invested in Boston Scientific (BSX) ten years ago? It may not have been easy to hold on to BSX for all that ...

This cohort will compare the Medtronic Prevail DCB with Boston Scientific AGENT DCB ... It will compare the Prevail DCB ...